KRAS vaccine for colorectal and pancreatic cancer after surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and in good enough health to be up and about (ECOG 0-1).
- You have had surgery to remove all visible cancer (R0) and completed at least 4 cycles of chemo after surgery.
- Your cancer stage is IIIA, IIIB, or IIIC for colorectal, or stage I, II, or III for pancreatic cancer, and your tumor has a specific KRAS mutation (like G12D, G12V, etc.).
- You have no signs of cancer spread or recurrence on scans.
- Your blood counts, liver/kidney function, and clotting tests are within a safe range.
- You are not pregnant, not breastfeeding, and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This study collects information from patients with pancreatic cancer that has a specific genetic change called a KRAS mutation, who have already received treatment targeting this mutation. Researchers will track outcomes to better understand how these treatments work.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.